Fly News Breaks for March 20, 2017
Mar 20, 2017 | 07:30 EDT
Ladenburg Thalmann analyst Matt Kaplan recommends using Friday's weakness in shares of Stemline Therapeutics as a buying opportunity. Following the disclosure of a death, the analyst tells investors that Stemline's patients are complicated with systemic disease impacting multiple organs. It is not uncommon to observe increased rates of cardiovascular issues including pericardial effusion and stroke in these patients, Kaplan tells investors in a research note. The data continue to "strongly support" the approval of SL-401 if the efficacy for the new cohort of patients is consistent with the prior data, the analyst contends. He reiterates a Buy rating on Stemline with a $41 price target.
News For STML From the Last 2 Days
There are no results for your query STML